List of Excipients in Branded Drug ONUREG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Celgene Corporation	ONUREG	azacitidine	59572-730	CELLULOSE, MICROCRYSTALLINE
Celgene Corporation	ONUREG	azacitidine	59572-730	CROSCARMELLOSE SODIUM
Celgene Corporation	ONUREG	azacitidine	59572-730	MAGNESIUM STEARATE
Celgene Corporation	ONUREG	azacitidine	59572-730	MANNITOL

ONUREG Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Onureg is an oral azacitidine product developed by Bristol Myers Squibb for maintenance treatment of acute myeloid leukemia. Its commercial value comes from converting azacitidine from an injectable treatment into a chronic oral regimen. The core excipient opportunity is not basic tablet manufacture. It is the development of a stable, reproducible oral dosage form that supports 300 mg dosing on Days 1 through 14 of each 28-day cycle while maintaining dose uniformity, dissolution performance, tolerability, and regulatory substitutability.

The product has meaningful commercial barriers: azacitidine is chemically and biologically sensitive, Onureg has a protected clinical regimen, oral and injectable azacitidine are not interchangeable, and generic developers must reproduce the product's pharmaceutical performance through the ANDA pathway. Excipients can create differentiated opportunities in stability, process control, patient acceptability, packaging, and manufacturing economics.

What is Onureg and how is its formulation positioned?

Onureg contains azacitidine, the same active pharmaceutical ingredient used in Vidaza injection, but the products have different clinical use, pharmacokinetics, dosing schedules, and regulatory labels.

Attribute	Onureg
Active ingredient	Azacitidine
Dosage form	Oral film-coated tablet
Strengths	200 mg and 300 mg
Standard dose	300 mg orally once daily on Days 1-14 of a 28-day cycle
Sponsor	Bristol Myers Squibb, following Celgene acquisition
US approval	Sept. 1, 2020
Primary use	Maintenance treatment for adults with AML in first remission after intensive induction chemotherapy who are not able to complete intensive curative therapy
Key clinical study	QUAZAR AML-001
Regulatory pathway	New drug application
Generic pathway	Abbreviated new drug application, subject to product-specific requirements
FDA substitutability with injectable azacitidine	No automatic substitution

The FDA label identifies Onureg as a film-coated tablet containing azacitidine and inactive ingredients used in the tablet core and coating. Public labeling is useful for identifying the excipient platform, but it does not disclose the full manufacturing process, particle engineering, granulation parameters, coating process, or complete intellectual-property scope. (U.S. Food and Drug Administration, 2023a)

What excipients are used in Onureg tablets?

Onureg's disclosed excipient system is a conventional oral solid-dose platform built around a compressible tablet core and film coating. Public product information identifies excipients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and coating materials such as polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and colorants. Exact excipient composition and quantitative proportions should be taken from the applicable FDA label and product monograph for the jurisdiction under review. (U.S. Food and Drug Administration, 2023a; European Medicines Agency, 2021)

Functional role of the principal excipients

Excipient category	Likely function in Onureg
Lactose monohydrate	Diluent and tablet-mass contributor
Microcrystalline cellulose	Dry-binder, diluent, and compression aid
Croscarmellose sodium	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Polyvinyl alcohol or related film former	Coating matrix
Polyethylene glycol	Plasticizer
Talc	Anti-tacking and coating-process aid
Titanium dioxide and iron oxides	Opacification and product identification

The formulation strategy prioritizes immediate tablet disintegration and reliable azacitidine release rather than a modified-release profile. The critical development issue is not simply selecting fast-disintegrating excipients. It is controlling the interaction between azacitidine, water, compression force, lubricant level, coating conditions, and package humidity.

Why is excipient selection commercially important for azacitidine?

Azacitidine is a cytidine analog with stability and handling sensitivities that can affect assay, degradation products, dissolution, and shelf life. A formulation that performs well at initial release may fail under accelerated humidity or temperature conditions if the tablet core, coating, and packaging are not optimized together.

The main formulation risks are:

1. Moisture uptake and hydrolytic degradation.
2. Chemical interaction with reactive excipient impurities.
3. Slower disintegration after storage.
4. Compression-induced dissolution changes.
5. Blend segregation between azacitidine and high-load excipients.
6. Coating-related moisture exposure.
7. Batch-to-batch variability in a high-potency oncology product.

The commercial implication is that excipient suppliers can compete through controlled functionality rather than commodity pricing. Relevant value propositions include low-moisture grades, narrow particle-size distributions, low-peroxide materials, direct-compression performance, high-flow excipients, and excipients supported by robust extractables and leachables data.

What excipient strategies could improve Onureg or generic azacitidine tablets?

Moisture-control strategy

A generic developer may evaluate lower-moisture grades of lactose, microcrystalline cellulose, croscarmellose sodium, and coating polymers. The objective is to reduce water activity without compromising tablet hardness or disintegration.

Potential tools include:

• Low-loss-on-drying excipient grades.
• Controlled humidity during blending and compression.
• High-barrier blister packaging.
• Desiccant-supported bottles.
• Lower-water coating systems.
• In-process moisture monitoring.
• Moisture-sorption characterization by dynamic vapor sorption.

Packaging is part of the formulation strategy. A tablet that requires high-barrier packaging can still be commercially viable, but packaging cost, patient handling, and global supply complexity affect the product's margin.

Disintegration and dissolution strategy

Onureg is administered as a relatively high-strength tablet. The formulation must achieve acceptable mechanical strength while allowing rapid and consistent disintegration. Croscarmellose sodium, crospovidone, and sodium starch glycolate are possible platform alternatives for generic development, but replacing the reference excipient system can affect:

• Disintegration time.
• Dissolution profile.
• Tablet friability.
• Sensitivity to compression force.
• Stability after humidity exposure.
• Bioequivalence risk.

A generic sponsor should avoid treating superdisintegrants as interchangeable commodities. Grade, substitution level, particle morphology, and incorporation method can materially change performance.

Lubrication strategy

Magnesium stearate is effective but can impair wetting and dissolution when over-lubrication occurs. The process window may be narrow because high-shear or prolonged blending can create hydrophobic surfaces around drug and excipient particles.

Commercial opportunities exist for:

• Lower-lubricant formulations.
• Alternative vegetable-derived lubricants.
• Improved lubricant dispersion.
• Continuous blending with tighter residence-time control.
• Process analytical technology for blend uniformity and lubricant distribution.

A change in lubricant type or concentration may trigger additional comparative dissolution work and could complicate an ANDA formulation if the resulting product requires a broader justification.

Direct-compression strategy

A direct-compression formulation can reduce granulation equipment, water exposure, drying time, and manufacturing cost. It also reduces the number of unit operations that can affect azacitidine stability.

The principal risks are poor flow, segregation, content-uniformity failure, and sensitivity to compression-force changes. Co-processed excipients may offer a route to better flow and compactability, but a proprietary co-processed excipient can create supply and qualification risks for a generic manufacturer.

Patient-acceptability strategy

Onureg is used repeatedly over multiple treatment cycles. Tablet size, coating, swallowability, and gastrointestinal tolerability therefore have commercial relevance. A smaller tablet could improve adherence, but achieving the required dose in a smaller unit may require:

• Higher-density excipients.
• More efficient compression.
• Granule engineering.
• A bilayer or multiple-tablet presentation.
• A different strength architecture.

Any alternative presentation must preserve dose administration instructions and avoid creating confusion with the 200 mg and 300 mg strengths.

What patents protect Onureg and its formulation?

Onureg protection may involve several layers:

Protection layer	Strategic relevance
Active-ingredient or chemical patents	Usually limited where azacitidine is an established compound
Oral formulation patents	May cover excipient combinations, dosage forms, stability, or release characteristics
Method-of-use patents	May cover maintenance treatment in AML or specific patient populations
Dosing-regimen patents	May cover oral administration schedules such as repeated 28-day cycles
Manufacturing patents	May cover solid-state form, granulation, coating, or process controls
Regulatory exclusivity	Can delay generic approval independently of patent expiry
Trade secrets	May cover process parameters, impurity control, packaging, and scale-up

The FDA Orange Book must be used to identify the patents listed against the US Onureg NDA, their expiration dates, pediatric exclusivity, and any patent-dispute certifications. Orange Book listings can change through patent-list updates, delistings, litigation outcomes, and regulatory amendments. (U.S. Food and Drug Administration, 2024)

A formulation patent can be commercially important even where the active ingredient is old. The practical question is whether the patent claims require a particular excipient, concentration range, dissolution profile, stability result, or manufacturing step. A generic product may avoid infringement through a different excipient system, but that design-around must still meet FDA bioequivalence and quality requirements.

When does Onureg lose exclusivity?

Onureg's commercial exclusivity has several separate clocks.

FDA regulatory exclusivity

Onureg received approval in 2020 for a new use of an established active ingredient. The applicable regulatory exclusivity depends on the FDA's designation of the approval and the relevant statutory provisions. Regulatory exclusivity can prevent or delay certain abbreviated applications even if a patent challenge is unsuccessful.

The exact loss-of-exclusivity date should be determined from the FDA's current product-specific exclusivity records and Orange Book data rather than inferred from the approval date alone. Patent expiry and regulatory exclusivity may not end on the same date.

Patent expiry

Patent expiry is claim-specific and jurisdiction-specific. A patent covering a formulation may expire later than a patent covering a chemical compound. Patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and settlement agreements can alter the effective entry date.

The principal commercial conclusion is that Onureg's loss of exclusivity should be modeled as a range of potential generic-entry dates rather than as one date. The relevant scenarios are:

• Earliest noninfringing generic launch.
• Launch after successful Paragraph IV litigation.
• Launch after settlement-defined entry.
• Launch after all listed patents expire.
• Launch following an authorized generic arrangement.

What Paragraph IV challenges could affect Onureg?

A generic applicant can file a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation under the Hatch-Waxman framework and may provide a 180-day exclusivity opportunity to the first qualifying ANDA applicant with a Paragraph IV certification.

The main challenge points for Onureg would likely be:

• Whether the asserted claims cover the generic's excipient system.
• Whether the claims require specific dissolution or stability results.
• Whether the claimed dosing regimen is infringed by the proposed labeling.
• Whether the patent is valid over prior oral azacitidine formulations.
• Whether the generic can carve out a patented method of use.
• Whether the formulation patent claims are enabled and adequately described.

A noninfringing formulation can reduce litigation risk, but it does not eliminate the possibility of litigation if the reference product has broad formulation or method-of-use claims.

Which companies are challenging Onureg?

The publicly relevant competitive set includes generic drug manufacturers and contract development and manufacturing organizations capable of producing high-potency oral oncology tablets. Generic competition should be assessed through FDA tentative-approval records, ANDA litigation dockets, Orange Book patent certifications, and company pipeline disclosures.

No company should be treated as an established Onureg challenger solely because it has a generic oncology business. A credible challenger generally must have:

• An identified azacitidine oral product.
• An ANDA or equivalent regulatory filing.
• A public Paragraph IV notice or patent action.
• Manufacturing capacity for high-potency tablets.
• A stable supply of azacitidine API.
• A validated commercial packaging system.

Because Onureg is a small-molecule tablet, biosimilar risk is not the relevant framework. The relevant risk is generic substitution under the ANDA pathway. (U.S. Food and Drug Administration, 2023b)

How does Onureg compare with Vidaza?

Issue	Onureg	Vidaza
Administration	Oral	Subcutaneous or intravenous injection
Active ingredient	Azacitidine	Azacitidine
Main use in this context	AML maintenance after remission	Myelodysplastic syndromes and AML-related treatment settings
Dosing pattern	300 mg orally on Days 1-14 of each 28-day cycle	Clinically distinct injectable schedules
Substitutability	Not interchangeable with Vidaza	Not interchangeable with Onureg
Commercial advantage	Convenience and outpatient administration	Established injectable treatment and clinical familiarity
Formulation opportunity	Tablet stability, dissolution, packaging, adherence	Reconstitution, sterility, vial configuration, injectable stability

The two products should not be treated as interchangeable versions of the same medicine. Their clinical development programs established different pharmacokinetic and therapeutic roles. (U.S. Food and Drug Administration, 2023a)

What commercial opportunities exist in Onureg excipients?

The strongest opportunities are in differentiated excipient platforms and manufacturing services, not in undifferentiated commodity supply.

High-value opportunity areas

1. Low-moisture excipients for azacitidine tablets.
2. Co-processed direct-compression systems.
3. Low-peroxide and low-reactivity excipient grades.
4. High-barrier blister and bottle packaging.
5. Continuous manufacturing and real-time blend monitoring.
6. Functional coating systems with low water exposure.
7. Smaller, higher-density tablet designs.
8. Stability-enhancing formulation development services.
9. Second-source qualification for critical excipients.
10. Global regulatory packages supporting US, European, and other filings.

Excipient suppliers with strong oncology experience can create value by providing formulation data, not only material specifications. A package containing compatibility studies, moisture-isotherm data, dissolution impact, impurity profiles, and scale-up evidence can shorten development timelines.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are azacitidine stability, high-potency handling, content uniformity, and packaging performance. The main intellectual-property barriers are formulation claims, dosing-regimen claims, and method-of-use claims.

Geographic coverage matters because US, European, Canadian, Japanese, and other patent estates can have different expiry dates and claim scope. A formulation designed to avoid a US patent may still infringe a corresponding European patent. A global generic strategy therefore requires a jurisdiction-by-jurisdiction claim chart.

For originator lifecycle management, excipient changes can support:

• Improved shelf life.
• New packaging configurations.
• Alternative manufacturing sites.
• Pediatric or geriatric presentations.
• Supply continuity.
• Reduced tablet size.
• Regional formulation adaptation.

For generic manufacturers, the same changes create design-around options but also increase regulatory comparability work.

What is the commercial outlook for Onureg?

Onureg's commercial position depends on continued use of oral AML maintenance therapy, physician adoption, patient persistence, reimbursement, and the timing of generic entry. Its value is concentrated in a defined hematology population rather than a broad primary-care market.

The revenue exposure is sensitive to three factors:

• The number of patients achieving remission after induction.
• The proportion unable to complete intensive curative therapy.
• The duration of treatment across repeated 28-day cycles.

Generic entry could produce rapid price erosion because oral tablets are easier to distribute and substitute than complex biologics. The erosion rate will depend on the number of approved ANDAs, first-filer status, contracting strategy, and whether the reference product retains method-of-use or formulation protection.

Key Takeaways

• Onureg is an oral azacitidine tablet approved in the US in 2020 for AML maintenance treatment.
• Its disclosed excipient platform is conventional, but azacitidine stability makes excipient grade and process control commercially important.
• The highest-value excipient opportunities involve moisture control, direct compression, low-reactivity materials, coating systems, and high-barrier packaging.
• Onureg and Vidaza are not interchangeable despite containing the same active ingredient.
• Generic competition will arise through the ANDA pathway, not the biosimilar pathway.
• Orange Book listings, Paragraph IV certifications, patent litigation, and settlement terms determine the practical generic-entry timeline.
• Excipient design-around strategies can reduce patent risk but may increase bioequivalence and stability-development risk.
• Global commercial planning requires separate analysis of US, European, and other jurisdictional patent estates.

FAQs

Is Onureg an immediate-release or extended-release tablet?

Onureg is an oral film-coated tablet designed to deliver azacitidine through an oral solid dosage form. Public labeling does not position it as a conventional extended-release product.

Can a generic manufacturer use different excipients from Onureg?

Yes. A generic manufacturer can generally use a different excipient system if the product satisfies FDA quality, bioequivalence, dissolution, stability, labeling, and patent requirements.

Is Onureg interchangeable with injectable azacitidine?

No. Onureg and injectable azacitidine have different dosing schedules, pharmacokinetics, clinical uses, and regulatory labeling.

Do excipients create patent risk for an Onureg generic?

They can. Patent claims may require particular excipients, concentration ranges, manufacturing steps, dissolution properties, or stability results. A formulation design-around must be assessed against each asserted claim.

What is the most attractive commercial opportunity in the Onureg supply chain?

The strongest opportunity is a stability-focused oral-solid-dose platform combining low-moisture excipients, controlled compression, protective coating, high-barrier packaging, and regulatory support for generic or lifecycle-management development.

References

1. European Medicines Agency. (2021). Onureg: EPAR product information. https://www.ema.europa.eu/

2. U.S. Food and Drug Administration. (2023a). Onureg (azacitidine) tablets: Prescribing information. Bristol Myers Squibb.

3. U.S. Food and Drug Administration. (2023b). Generic drugs: Questions and answers. https://www.fda.gov/drugs/questions-answers-generic-drugs

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm